USPTO Letter to FDA CDER Regarding Patent-Regulatory Coordination

The USPTO issued a letter to FDA's Center for Drug Evaluation and Research concerning patent regulatory matters. The document was posted as a final notice in the FDA regulations docket on Regulations.gov under docket FDA-2026-E-3826-0001. The correspondence appears to address coordination between intellectual property and pharmaceutical regulatory review processes.

Affected parties should monitor for any subsequent regulatory actions or guidance that may result from this inter-agency communication. The letter does not itself establish binding compliance obligations but may signal areas of regulatory focus or coordination between USPTO and FDA CDER.